Driehaus Capital Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-242,938
| Closed | -$21.5M | – | 430 |
|
|
2025
Q1 | $21.5M | Buy |
+242,938
| New | +$23.7M | 0.21% | 147 |
|
|
2024
Q3 | – | Sell |
-358,255
| Closed | -$38.6M | – | 389 |
|
|
2024
Q2 | $38.6M | Buy |
358,255
+180,043
| +101% | +$18M | 0.37% | 84 |
|
|
2024
Q1 | $16.9M | Buy |
+178,212
| New | +$15.3M | 0.17% | 179 |
|
|
2022
Q2 | – | Sell |
-133,690
| Closed | -$8.54M | – | 366 |
|
|
2022
Q1 | $8.54M | Sell |
133,690
-181,949
| -58% | -$13.1M | 0.1% | 253 |
|
|
2021
Q4 | $33.8M | Buy |
315,639
+140,480
| +80% | +$14.7M | 0.35% | 95 |
|
|
2021
Q3 | $18M | Buy |
175,159
+51,961
| +42% | +$4.84M | 0.21% | 145 |
|
|
2021
Q2 | $10.8M | Sell |
123,198
-7,996
| -6% | -$733K | 0.14% | 211 |
|
|
2021
Q1 | $12.8M | Buy |
131,194
+4,450
| +4% | +$444K | 0.19% | 168 |
|
|
2020
Q4 | $14.2M | Sell |
126,744
-4,576
| -3% | -$482K | 0.23% | 124 |
|
|
2020
Q3 | $12.2M | Buy |
131,320
+56,586
| +76% | +$4.36M | 0.25% | 113 |
|
|
2020
Q2 | $5.83M | Buy |
74,734
+31,468
| +73% | +$2.13M | 0.14% | 173 |
|
|
2020
Q1 | $2.53M | Sell |
43,266
-17,037
| -28% | -$1.1M | 0.08% | 210 |
|
|
2019
Q4 | $4.83M | Sell |
60,303
-14,332
| -19% | -$1.07M | 0.13% | 188 |
|
|
2019
Q3 | $5.48M | Sell |
74,635
-39,239
| -34% | -$3.39M | 0.18% | 142 |
|
|
2019
Q2 | $10.7M | Sell |
113,874
-14,457
| -11% | -$1.19M | 0.34% | 82 |
|
|
2019
Q1 | $10.3M | Buy |
128,331
+109,336
| +576% | +$8.08M | 0.39% | 72 |
|
|
2018
Q4 | $1.02M | Hold |
18,995
| – | – | 0.04% | 277 |
|
|
2018
Q3 | $1.48M | Sell |
18,995
-119,098
| -86% | -$8.28M | 0.05% | 317 |
|
|
2018
Q2 | $8.77M | Sell |
138,093
-158,196
| -53% | -$12.6M | 0.3% | 106 |
|
|
2018
Q1 | $27.2M | Buy |
296,289
+15,229
| +5% | +$1.31M | 0.96% | 15 |
|
|
2017
Q4 | $21.2M | Buy |
281,060
+95,325
| +51% | +$6.71M | 0.8% | 23 |
|
|
2017
Q3 | $12.9M | Sell |
185,735
-381,042
| -67% | -$20.4M | 0.5% | 43 |
|
|
2017
Q2 | $28.7M | Sell |
566,777
-324,914
| -36% | -$13.8M | 1.06% | 14 |
|
|
2017
Q1 | $35.7M | Sell |
891,691
-169,934
| -16% | -$6.08M | 1.22% | 13 |
|
|
2016
Q4 | $29.8M | Buy |
1,061,625
+151,004
| +17% | +$4.55M | 1.05% | 17 |
|
|
2016
Q3 | $27M | Buy |
910,621
+150,318
| +20% | +$3.73M | 0.91% | 19 |
|
|
2016
Q2 | $15.4M | Buy |
760,303
+98,586
| +15% | +$1.79M | 0.55% | 34 |
|
|
2016
Q1 | $11.9M | Sell |
661,717
-18,443
| -3% | -$320K | 0.39% | 48 |
|
|
2015
Q4 | $17.9M | Buy |
680,160
+93,201
| +16% | +$2.1M | 0.6% | 31 |
|
|
2015
Q3 | $12.5M | Buy |
586,959
+79,132
| +16% | +$2.19M | 0.45% | 53 |
|
|
2015
Q2 | $13.5M | Buy |
+507,827
| New | +$14.5M | 0.47% | 49 |
|
Other funds holding BPMC
PCM
UOC
Driehaus Capital Management's BPMC Position: Q2 2025 in Review
Driehaus Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 242,938 shares — an estimated $21.5M sold.
Driehaus Capital Management first reported a position in BPMC in Q2 2015 and held it in 31 quarters. The position peaked at $38.6M in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.
- Driehaus Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
- Driehaus Capital Management sold 242,938 Blueprint Medicines shares in Q2 2025, an estimated $21.5M.
- Driehaus Capital Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 31 quarters.
- Driehaus Capital Management's Blueprint Medicines position peaked at $38.6M in Q2 2024.
- 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.
Based on Driehaus Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.